Novel Method Development for Metformin, Ivabradine, Metoprolol and Ertugliflozin and its Validation in API and Pharmaceutical Dosage Form by RPHPLC Method

Author:

Haritha G.1,Aanandhi M Vijey2,Shanmugasundaram P.3

Affiliation:

1. Research Scholar, Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India.

2. Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India.

3. Director, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India.

Abstract

Present investigation is based upon a new method development and validation for the simultaneous estimation of drugs comes under the classification of anti-hypertensive and anti-diabetic. For the proposed method metformin, ivabradine, metoprolol and ertugliflozin drugs were selected. The chromatographic separation was achieved by using mobile phase 0.01N potassium dihydrogen ortho phosphate buffer and acetonitrile (50:50) ratio and stationary phase of kromasil C18(250×4.6mm, 5µm) column. The retention times for metformin, ivabradine, metoprolol and ertugliflozin were found to be 2.560min, 3.116 min, 3.473 min and 5.196 min respectively. The developed method shows that all the drugs were clearly separated among each other with the system suitability. The developed method was further validated as per ICH guidelines Q2R1. It was found the method was accurate, presice with good linearity. Hence this method can be used for the routine analysis of these drugs in biological sample.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference16 articles.

1. Available at https://www.who.int/news-room/facts-in-pictures/detail/diabetes,21st February,2018.

2. Diabetes Care. 2004; 27(5): 1047-1053. Available at https://doi.org/10.2337/diacare.27.5.1047

3. Government survey found 11.8% prevalence of diabetes in India, 2 min read. 2019; IST Neetu Chandra Sharma. Available at https://www.livemint.com/science/health/government-survey-found-11-8-prevalence-of-diabetes-in-india-11570702665713.html.

4. Available at https://www.dailyexcelsior.com/dr-rampal-delivers-lecture-on-diabetes-in-up/

5. Available at https://www.who.int/news-room/fact-sheets/detail/hypertension

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3